-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Gilead Sciences, Lowers Price Target to $156

Benzinga·07/07/2026 12:23:05
Listen to the news
Truist Securities analyst Gregory Renza maintains Gilead Sciences (NASDAQ:GILD) with a Buy and lowers the price target from $157 to $156.